ArticleBMC physiology2005
Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha.
Article in BMC physiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 67 citations in OpenAlex.
- A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.World journal of gastroenterology · 2008Trial
- Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.Neurochemical research · 2021Review
- Chronic Low-Dose Alcohol Consumption Attenuates Post-Ischemic Inflammation via PPARγ in Mice.International journal of molecular sciences · 2021Article
- Endothelial PPARγ Is Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK.Neurotoxicity research · 2019Review
- Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A.Mediators of inflammation · 2018Article
- A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis.Scientific reports · 2017Article
- Milk-derived bioactive peptides and their health promoting effects: a potential role in atherosclerosis.British journal of clinical pharmacology · 2017Review
- PPARγ ameliorated LPS induced inflammation of HEK cell line expressing both human Toll-like receptor 4 (TLR4) and MD2.Cytotechnology · 2016Article
- Altered Clock and Lipid Metabolism-Related Genes in Atherosclerotic Mice Kept with Abnormal Lighting Condition.BioMed research international · 2016Article
- Identification, by systematic RNA sequencing, of novel candidate biomarkers and therapeutic targets in human soft tissue tumors.Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Endothelial PPAR-γ protects against vascular thrombosis by downregulating P-selectin expression.Arteriosclerosis, thrombosis, and vascular biology · 2015Article
- Milk-derived bioactive peptides inhibit human endothelial-monocyte interactions via PPAR-γ dependent regulation of NF-κB.Journal of inflammation (London, England) · 2015Article
- The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.The Journal of biological chemistry · 2014Article
- 9-cis-retinoic Acid and troglitazone impacts cellular adhesion, proliferation, and integrin expression in K562 cells.PloS one · 2014Article
- PPAR-γ -- a possible drug target for complicated pregnancies.British journal of pharmacology · 2013Review
- Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease.Journal of clinical biochemistry and nutrition · 2011Article
- Role of the endothelium in inflammatory bowel diseases.World journal of gastroenterology · 2011Review
- The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.Journal of the American Society of Nephrology : JASN · 2009Article
- PPARgamma-independent antitumor effects of thiazolidinediones.Cancer letters · 2009Review
- AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.Clinical science (London, England : 1979) · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundCytokine mediated induction of the mucosal addressin cell adhesion molecule-1(MAdCAM-1) expression is associated with the onset and progression of inflammatory bowel disease (IBD).
resultsUsing western blotting and cell-based ELISA, we show in this study that troglitazone, an activator of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), widely used in the treatment of diabetes, has as well recently been highlighted as protective in models of inflammation and cancer. We found that troglitazone (10-40 microM), significantly reduced the TNF-alpha (1 ng/ml) mediated induction of endothelial MAdCAM-1 in a dose-dependent manner, achieving a 34.7% to 98.4% reduction in induced MAdCAM-1. Trogliazone (20 microM) reduced TNF-alpha induced VCAM-1, ICAM-1 and E-selectin expression. Moreover, troglitazone significantly reduced alpha4beta7-integrin dependent lymphocyte adhesion to TNF-alpha cultured endothelial cells.
conclusionsThese results suggest that PPAR-gamma agonists like troglitazone may be useful in the clinical treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.